MXCTHealthcare · Medical DevicesMXCT Stock Forecast: MaxCyte, Inc. Price Predictions for 2026-2027
The 6 Wall Street analysts covering MaxCyte, Inc. hold a median 12-month price target of $4.5 — +320.6% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 62 of 100 as at 1 Aug 2026 — in the upper half.
MXCT stock analysis: one number for the whole business
Consensus tells you what everyone already believes. The model scores MaxCyte, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Growth (85): Sales and profits are climbing, and climbing faster than before.
Momentum (17): The shares have been drifting down relative to others.
The rank is the raw material. Whether the rules would actually own MaxCyte, Inc. — and when they’d sell — is the membership.
MXCT stock forecast 2026-2027: analyst price targets & predictions
The bullish and bearish analyst opinions on MXCT, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
The green dot is the last close — the median target sits +320.6% from it.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 25 Mar 2026 | Craig-Hallum | Maintains | Buy | $7.00 → $5.00 |
| 11 Aug 2025 | BTIG | Downgrade | Neutral | — |
| 7 Aug 2025 | William Blair | Downgrade | Market Perform | — |
| 22 July 2025 | Stephens & Co. | Assumes | Overweight | $6.00 |
| 12 Mar 2025 | Stifel | Maintains | Buy | — |
| 23 Apr 2024 | Stephens & Co. | Reiterates | Overweight | — |
| 13 Mar 2024 | BTIG | Maintains | Buy | — |
| 13 Mar 2024 | Stephens & Co. | Reiterates | Overweight | — |
| 29 Nov 2023 | Craig-Hallum | Initiates | Buy | — |
| 5 Oct 2023 | Stephens & Co. | Reiterates | Overweight | — |
| 28 Mar 2023 | Stephens & Co. | Reiterates | Overweight | — |
| 15 Aug 2022 | BTIG | Maintains | Buy | — |
| 24 Aug 2021 | BTIG | Initiates | Buy | — |
| 24 Aug 2021 | Cowen & Co. | Initiates | Outperform | — |
| 24 Aug 2021 | Stephens & Co. | Initiates | Overweight | — |
| 24 Aug 2021 | Stifel | Initiates | Buy | — |
| 24 Aug 2021 | William Blair | Initiates | Outperform | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
MXCT analyst estimate revisions
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
MaxCyte, Inc. (MXCT) financial data
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
- Trailing P/E
- −2.5×
- Price / sales
- 3.5×
- Price / book
- 0.7×
- EV / EBITDA
- −0.7×
Cheaper than 86% of US stocks
Cheaper than 37% of US stocks
Cheaper than 81% of US stocks
Cheaper than 66% of US stocks
- Revenue growth (YoY)
- −7.1%
- Earnings growth (YoY)
- −7.1%
- Gross margin
- 83.7%
- Operating margin
- −64.1%
- Net margin
- −121.2%
Higher than 19% of US stocks
Higher than 29% of US stocks
Higher than 93% of US stocks
Higher than 16% of US stocks
Higher than 5% of US stocks
- Return on equity
- −21.3%
- Return on assets
- −11.3%
- Dividend yield
- —
Higher than 30% of US stocks
Higher than 26% of US stocks
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
MXCT vs competitors
The nearest names by industry and size, scored by the same model — like for like.
This page is one stock. Monday covers all of them.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. MXCT appears on the weeks it earns a place.
Frequently asked questions about MXCT stock
What is the MXCT stock price forecast for 2026-2027?
The 6 Wall Street analysts covering MaxCyte, Inc. have a median 12-month price target of $4.5, with estimates ranging from $2.43 to $5. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Is MXCT stock a buy right now?
Of the 6 analysts covering MaxCyte, Inc., 5 rate it a Buy, 1 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks MaxCyte, Inc. 62 out of 100 across roughly 4,600 US stocks as at 1 Aug 2026. None of this is personal advice — it does not consider your circumstances.
How does Ticker Nerd's model rank MXCT?
As at 1 Aug 2026, MaxCyte, Inc. ranks 62 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Growth (85 of 100).
Will MXCT stock go up?
No one can know that. What the data says: the median 12-month target from 6 analysts implies +320.6% from the last close, and Ticker Nerd's factor model ranks MaxCyte, Inc. 62 out of 100 as at 1 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
What is the MXCT stock forecast for 2030?
No analyst covering MaxCyte, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for MXCT are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $2.43 to $5 over the next 12 months.
How has MXCT stock performed over the past year?
MaxCyte, Inc. returned -47.5% over the 12 months to 3 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.
What does MaxCyte, Inc. do?
MaxCyte, Inc. is a commercial cell-engineering company that provides enabling platform technologies to advance the discovery, development, and commercialization of next-generation cell-based therapeutics.
About MaxCyte, Inc.
MaxCyte, Inc. is a commercial cell-engineering company that provides enabling platform technologies to advance the discovery, development, and commercialization of next-generation cell-based therapeutics. Its proprietary Flow Electroporation platform and ExPERT instrument portfolio, including ExPERT ATx for small to medium scale transfection, ExPERT STx for protein production and drug development, ExPERT GTx for large scale therapeutic applications, and ExPERT VLx for very large volume cell-engineering, deliver high transfection efficiency, cell viability, and scalability. The company also offers disposable processing assemblies, electroporation buffers, software protocols, and SeQure DX services for on-target and off-target editing assessments. MaxCyte generates revenue through sales of instruments, consumables, licenses, and its Strategic Platform License program, which grants partners non-exclusive rights for research, clinical, and commercial use, including milestone payments and royalties. These technologies support diverse cell types and payloads in cell and gene therapies for cancer, autoimmune diseases, and other areas, serving pharmaceutical and biotechnology companies worldwide. Founded in 1998 and headquartered in Rockville, Maryland, MaxCyte plays a key role in the biotechnology sector by facilitating precise, efficient, and GMP-ready cell engineering.
CEO Mr. Maher Masoud · 114 employees · United States · https://www.maxcyte.com